Shattuck Labs (STTK) Net Income towards Common Stockholders (2019 - 2026)
Shattuck Labs (STTK) reported Net Income towards Common Stockholders of -$14.8 million for Q1 2026, down 7.78% year-over-year from -$16.0 million in Q1 2025, and down 10.43% quarter-over-quarter from -$13.4 million in Q4 2025.
Shattuck Labs (STTK) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$14.8 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$14.8 million, down 7.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$51.9 million (up 30.1% YoY), and the FY2025 annual result was -$48.8 million, up 35.27% from the prior year.
- Net Income towards Common Stockholders eased to -$14.8 million in Q1 2026 per STTK's latest filing, from -$13.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$10.7 million in Q3 2025 and troughed at -$28.6 million in Q3 2023.
- A 5-year average of -$20.1 million and a median of -$20.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 431.6% in 2022, then jumped 43.25% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$26.3 million in 2022, then grew by 27.88% to -$19.0 million in 2023, then fell by 3.64% to -$19.6 million in 2024, then surged by 31.92% to -$13.4 million in 2025, then dropped by 10.43% to -$14.8 million in 2026.
- Business Quant data shows STTK's Net Income towards Common Stockholders at -$14.8 million in Q1 2026, -$13.4 million in Q4 2025, and -$10.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Shattuck Labs | 190.32 Mn | 190.32 Mn | - | -14.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.77 Mn |
| Dec 31, 2025 | -13.37 Mn |
| Sep 30, 2025 | -10.72 Mn |
| Jun 30, 2025 | -13.03 Mn |
| Mar 31, 2025 | -13.70 Mn |
| Dec 31, 2024 | -19.64 Mn |
| Sep 30, 2024 | -17.92 Mn |
| Jun 30, 2024 | -22.96 Mn |
| Mar 31, 2024 | -20.04 Mn |
| Dec 31, 2023 | -18.95 Mn |
| Sep 30, 2023 | -28.60 Mn |
| Jun 30, 2023 | -22.75 Mn |
| Mar 31, 2023 | -21.66 Mn |
| Dec 31, 2022 | -26.28 Mn |
| Sep 30, 2022 | -25.23 Mn |
| Jun 30, 2022 | -27.66 Mn |
| Mar 31, 2022 | -24.17 Mn |
| Dec 31, 2021 | 7.92 Mn |
| Sep 30, 2021 | -17.33 Mn |
| Jun 30, 2021 | -23.51 Mn |